Background: Paracetamol is a common antipyretic/analgesic and a component of many prescription and over- the- counter preparations. Hypersensitivity reactions to paracetamol appear to be increasing, but there are few prevalence data. The mechanism is poorly understood. We identified the clinical features of 32 patients with suspected paracetamol allergy, investigated the underlying mechanism and examined co-existing non-steroidal anti-inflammatory drug (NSAID) tolerance. Methods: A clinical history was taken and skin tests and an oral challenge were performed in 32 patients with suspected paracetamol allergy. Results: Patients presented with a combination of urticaria, angio-oedema (face, hands), erythema (cutaneous features in 94%), dyspnoea (including laryngeal oedema), rhinoconjunctivitis, cough, abdominal pain and anaphylaxis. Two patients had a positive skin prick test (SPT) and unequivocal history of acute urticaria/facial angio-oedema/conjunctivitis/cough after paracetamol with no other triggers. One patient had a positive intradermal test. Oral challenge was positive in 15 of 31 patients (including self-challenge in 4), triggering (a combination of) rhinitis, conjunctivitis, pruritus, erythema, urticaria, angio-oedema, dyspnoea and abdominal pain. Sensitivity was evident in 1 patient on the basis of the patient’s history. Overall, paracetamol hypersensitivity was confirmed in 16 of the 32 patients (50%). Twelve of the 16 paracetamol-allergic patients (75%) tolerated NSAIDs (negative challenge in 6, negative history in 6). Four of these 16 patients (25%) were intolerant of NSAIDs (positive challenge in 1, self-challenge in 3). Conclusions: In past reports on paracetamol hypersensitivity, only single cases of a positive SPT and detectable specific IgE have been described. Our data confirm that specific IgE may be a mechanism underlying paracetamol hypersensitivity, as in this series 18.8% of the patients had specific IgE. In 81.2% of patients, negative skin tests did not exclude paracetamol hypersensitivity, suggesting that it may be mediated by leukotrienes. However, three quarters of our patients tolerated NSAIDs, implicating an alternative mechanism. In patients with suspected paracetamol allergy, skin tests should be performed in addition to clinical history and oral challenge.

Keywords:
Drug allergy, Drug reaction, IgE antibodies, specific, Paracetamol, Acetaminophen
1.
Farquhar H, Crane J, Mitchell EA, Eyers S, Beasley R: The acetaminophen and asthma hypothesis 10 years on: a case to answer. J Allergy Clin Immunol 2009;124:649–651.
2.
Perzanowski MS, Miller RL, Tang D, Ali D, Garfinkel RS, Chew GL, et al: Prenatal acetaminophen exposure and risk of wheeze at age 5 years in an urban low-income cohort. Thorax 2010;65:118–123.
3.
Lowe AJ, Carlin JB, Bennett CM, Hosking CS, Allen KJ, Robertson CF, et al: Paracetamol use in early life and asthma: prospective birth cohort study. BMJ 2010;341:c4616.
4.
Eneli I, Sadri K, Camargo C, Barr RG: Acetaminophen and the risk of asthma. The epidemiologic and pathophysiologic evidence. Chest 2005;127:604–612.
5.
Shaheen S, Potts J, Gnatiuc L, Makowska J, Kowalski ML, Joos G, et al: The relation between paracetamol use and asthma: a GA2LEN European case-control study. Eur Respir J 2008;32:1231–1236.
6.
Beasley R, Clayton T, von Mutius E, Lai CKW, Montefort S, Stewart L: Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis and eczema in children aged 6–7: analysis from Phase Three of the ISAAC programme. Lancet 2008;372:1039–1047.
7.
Ibanez MD, Alonson E, Munoz MC, Martinez E, Laso MT: Delayed hypersensitivity reaction to paracetamol (acetaminophen). Allergy 1996;51:121–123.
8.
Boussetta K, Ponvert C, Karila C, le Bourgeois M, de Blic J, Scheinmann P: Hypersensitivity reactions to paracetamol in children: a study of 25 cases. Allergy 2005;60:1174–1177.
9.
Mendizabal SL, Diez Gomez ML: Paracetamol hypersensitivity without aspirin intolerance. Allergy 1998;53:457–458.
10.
Stricker BH, Meyboom RH, Lindquist M: Acute hypersensitivity reactions to paracetamol. BMJ 1985;291:938–939.
11.
Kogan MD, Pappas G, Yu SM, Kotelchuck M: Over-the-counter medication use among US preschool children. JAMA 1994;272:1025–1030.
12.
Newson RB, Shaheen SO, Chinn S, Burney PGJ: Paracetamol sales and atopic disease in children and adults: an ecological analysis. Eur Respir J 2000;16:817–823.
13.
Holgate ST: The acetaminophen enigma in asthma. Am J Respir Crit Care Med 2011;183:147–148.
14.
Barr GR: Does acetaminophen cause asthma in children? Time to remove the guesswork. Lancet 2008;372:1011–1012.
15.
Doña I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J, et al: Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy 2011;41:86–95.
16.
Martin JA, Lazaro M, Cuevas M, Alvarez Cuesta E: Paracetamol anaphylaxis. Clin Exp Allergy 1993;23:534.
17.
Messaad D, Sahla H, Godard P. Busquet J, Demoly P: Drug provocation tests in patients with a history suggesting an immediate hypersensitivity reaction. Ann Intern Med 2004;140:1001–1006.
18.
Kvedariene V, Bencheriuoa AM, Messaad D, Godard P, Busquet J, Demoly P: The accuracy of the diagnosis of suspected paracetamol (acetaminophen) hypersensitivity: results of a single-blinded trial. Clin Exp Allergy 2002;32:1366–1369.
19.
Kivity S, Pawlik I, Katz Y: Acetaminophen hypersensitivity. Allergy 1999;54:187–188.
20.
Vieluf D, Vieluf I, Brockow K: Positive intracutaneous and oral provocation test in a child with an anaphylactoid reaction to paracetamol. J Allergy Clin Immunol 1996;97:346.
21.
Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P: General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002;57:45–51.
22.
Barbaud A, Goncalo M, Bruynzeel D, Bircher A: Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reaction. Contact Derm 2001;45:321–328.
23.
Mirakian R, Ewan PW, Durham SR, Youlten LJF, Dugue P, Friedmann PS, et al: BSACI guidelines for the management of drug allergy. Clin Exp Allergy 2009;39:43–61.
24.
Ownby DR: Acetaminophen-induced urticaria and tolerance of ibuprofen in an eight-year-old child. J Allergy Clin Immunol 1997;99:151–152.
25.
Roll A, Wutrich B, Schimid-Grendelmeier P, Hofbauer G, Ballmer-Weber BK: Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. Swiss Med Wkly 2006;136:684–690.
26.
de Paramo BJ, Gancedo SQ, Cuevas M, Camo IP, Martin JA, Cosmes EL: Paracetamol (acetaminophen) hypersensitivity. Ann Allergy Asthma Immunol 2000;85:508–511.
27.
Asero R: Multiple sensitivity to NSAID. Allergy 2000;55:893–894.
28.
Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD: Prevalence of cross-reactivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:480–485.
29.
Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet P, et al: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011;66:818–829.
30.
Qin N, Zhang SP, Reitz TL, Mei JM, Flores CM: Cloning, expression and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron-1 retention. J Pharmacol Exp Ther 2005;315:1298–1305.
31.
Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, et al: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 2002;99:13926–13931.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.